Dr Oleg Anichtchik

Dr Oleg Anichtchik

Honorary Lecturer in Clinical Neurobiology

Faculty of Health

Oleg can be contacted through arrangement with our Press Office, to speak to the media on these areas of expertise.
  • Alzheimer's disease
  • Dementia
  • Dementia clinical trials


2013 - present - Principal Investigator, Lecturer, Department of Clinical Neurobiology, Plymouth University Schools of Medicine and Dentistry.            



2001 - Ph.D. degree was awarded by the Faculty of Mathematics and Natural Sciences, Åbo Akademi University, Turku, Finland;

1996 - M.D. degree was awarded by the Faculty of the General Medicine, Grodno State Medical Institute, Grodno, Belarus. 

Previously held positions:

2010 - 2013 -
Alzheimer Research UK (ARUK) Senior Research fellow, Centre for Brain Repair, University of Cambridge, United Kingdom ;

2009 - 2012 - Clare College Research Associate, University of Cambridge, United Kingdom ;

2007-2010 - Postdoctoral fellow at Cambridge Centre for Brain Repair, University of Cambridge, United Kingdom;  

2005 - 2007 - Senior Research Associate, Daniolabs Ltd, Cambridge, United Kingdom;

2001 - 2004 - Finnish Academy of Sciences postdoctoral fellow, Institute of Biomedicine, Department of Anatomy, University of Helsinki, Finland;

1995 - 1996 - Junior researcher at the Laboratory of Morphology and Neurochemistry, Institute of Biochemistry, Academy of Sciences of Belarus, Grodno, Belarus.   

Professional membership

Fellow of the Higher Education Academy, UK; 

Member of the Society for Neuroscience, USA;

Member of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), USA.   



Research interests

Understanding mechanisms of insoluble protein aggregates formation and cellular degeneration in the human brain is one of the most pressing questions of clinical neurobiology. We are trying to understand the process of alpha-synuclein aggregation in the development of neurodegenerative disorders such as Parkinson's disease and dementia with Lewy bodies. In particular, we are looking for the reasons of a selective vulnerability of neurons to the toxic insult caused by aggregating proteins and whether dis-aggregating strategies could be beneficial in these conditions.  To address this, classical neuromorphology, biochemistry and cell biology techniques are used in the range of in vitro and in vivo models, including human post-mortem studies, animal models of neurodegeneration and cell culture assays.

Grants & contracts

2016 -        Alzheimer’s Research UK network centre grant, £25,000 (PI)

2016 -        BRACE Alzheimer's Research, £86,000 (PI)

2016 -        Northcott Devon Medical Foundation (UK), £7,000 (PI)

2015 -        British Neuropathological Society, £5,000 (PI)

2014 -        Alzheimer’s Research UK network centre grant , £25,000 (PI)